Although the main objective of the study was to evaluate the toxicity of the combined regimen, the treatment produced a high response rate (74%) and was well tolerated. Eight patients became amenable to hepatic cryosurgery. The selleck kinase inhibitor median progression-free and overall survivals were 8.1 and 17.2 months for patients who did not undergo cryosurgery. In the group that underwent cryosurgery, median time to progression was 17.3 months. During a median follow-up of

26.4 months after surgery, only one patient died of disease. In another phase I experience Inhibitors,research,lifescience,medical using HAI FUDR and dexamethasone along with systemic oxaliplatin combinations (A: oxaliplatin and irinotecan or B: oxaliplatin and 5-FU/LV) in 36 patients with unresectable liver metastases, response and survival were again high (36). In this series, 89% of the patients had received prior chemotherapy, and 69.4% had prior irinotecan. The partial response rates were 90% and 87% for arms A and B, respectively. Seven patients Inhibitors,research,lifescience,medical in group A were able to undergo hepatic resection. The median survival time was 35.8 and 22 months for groups A and B, respectively. In a more recent study, the results in Arm A were confirmed. In 49 patients, response rate was 92% with a median survival

of 41 months from the Inhibitors,research,lifescience,medical time of HAI therapy initiation, even though 53% were previously treated (36). In a retrospective analysis, Gallagher et al. (41) reported a high partial response rate (44%) with systemic irinotecan plus HAI FUDR/dexamethasone in patients with metastatic CRC to the liver who progressed on oxaliplatin-based chemotherapy. The median survival was 20 months from the start of HAI therapy and 18% of patients were able to undergo surgical resection or ablation. Administration of newer chemotherapy agents via HAI associated with systemic 5-FU-based therapy may be another Inhibitors,research,lifescience,medical approach in this setting. In a phase I study, 21 patients with hepatic metastases from CRC were treated with HAI oxaliplatin plus intravenous 5-FU/LV (42). The treatment regimen, which was administered every 3 weeks, consisted of 5-FU 600 mg/m2 and LV 200 mg/m2 intravenous combined with 25 mg/m2 oxaliplatin HAI with

dose Inhibitors,research,lifescience,medical increments of 25 mg/m2. The limiting toxicities observed at an oxaliplatin dose of 150 mg/m2/cycle were leukopenia, occlusion of the hepatic artery, and acute pancreatitis. The recommended dose was 125 mg/m2 every 3 weeks. Overall, Farnesyltransferase 24% of the patients achieved a complete response, with an overall response rate of 59%. The median time to progression had not been reached at the cutoff date, with a median follow-up of 6.7 months. In another phase I-II study conducted by Fiorentini et al. (43), 12 previously-treated (irinotecan, oxaliplatin and/or 5-FU/LV) patients with progressive CRC liver metastases received HAI with oxaliplatin as a 30 minute infusion every 3 weeks. Dose-limiting toxicity was observed at 175 mg/m2/cycle and consisted of occlusion of the hepatic artery, abdominal pain and severe hypotension.